drugset / Trial / NCT06274528
DORA and LP in Alzheimer's Disease Biomarkers
Phase 2
Recruiting
201 enrolled
University of Minnesota
Eisai Inc. · collabNational Institute on Aging (NIA) · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to see if the sleep aid, lemborexant, can decrease the amount of amyloid-beta and tau in the blood. Amyloid-beta and tau are proteins involved in the disease process leading to Alzheimer's disease.
Timeline
- Start
- 2024-03-11
- Primary completion
- 2030-03-31
- Completion
- 2030-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lemborexant | Small molecule | 10 mg | Oral |
| Subject | Lemborexant | Small molecule | 20 mg | Oral |